ENTRADA THERAPEUTICS INC. - COMMON STOCK

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

10 8 2023 07:00:00 提供 Nasdaq GlobeNewswire

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

08 8 2023 07:00:01 提供 Nasdaq GlobeNewswire

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

01 8 2023 07:00:00 提供 Nasdaq GlobeNewswire

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

06 6 2023 07:00:01 提供 Nasdaq GlobeNewswire

Entrada Therapeutics Reports First Quarter 2023 Financial Results

10 5 2023 07:00:01 提供 Nasdaq GlobeNewswire

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

04 4 2023 07:00:00 提供 Nasdaq GlobeNewswire

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

29 3 2023 07:00:00 提供 Nasdaq GlobeNewswire

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

06 3 2023 07:00:01 提供 Nasdaq GlobeNewswire

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

27 2 2023 07:00:00 提供 Nasdaq GlobeNewswire

Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)

09 2 2023 07:00:00 提供 Nasdaq GlobeNewswire

Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable

09 1 2023 07:00:01 提供 Nasdaq GlobeNewswire

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

19 12 2022 16:30:00 提供 Nasdaq GlobeNewswire

Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference

22 11 2022 07:00:00 提供 Nasdaq GlobeNewswire

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

07 11 2022 07:00:01 提供 Nasdaq GlobeNewswire

Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

30 8 2022 07:00:00 提供 Nasdaq GlobeNewswire

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

11 8 2022 07:00:02 提供 Nasdaq GlobeNewswire

Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1

04 8 2022 07:00:03 提供 Nasdaq GlobeNewswire

Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer

19 7 2022 07:00:00 提供 Nasdaq GlobeNewswire

Entrada Therapeutics to Present at William Blair Biotech Focus Conference

06 7 2022 07:00:00 提供 Nasdaq GlobeNewswire

Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference

01 6 2022 07:00:02 提供 Nasdaq GlobeNewswire